source
- Upcoming FDA decisions in Q3 2026 could signal agency flexibilityThe piece highlights five FDA actions slated for the third quarter of 2026 that industry participants are tracking. Observers say the outcomes may reveal how flexible the agency will be under its…
- FDA approves Tregzi, first T‑reg cell therapy to lower chronic GVHD risk in blood‑cancer transplantsThe FDA announced approval of Tregzi, a regulatory T‑cell based immunotherapy designed to improve chronic graft‑versus‑host disease‑free survival for adults with blood cancers undergoing allogeneic…